Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$299
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
Semaglutide is a 34-amino acid GLP-1 receptor agonist analog with a C18 fatty diacid modification enabling reversible albumin binding.
Research interest centres on how fatty acid conjugation modulates receptor binding kinetics, internalisation rates, and cAMP desensitisation relative to shorter-acting GLP-1 analogs. The high GLP-1R selectivity (versus GcgR or GIPR) makes it a clean single-pathway reference standard in multi-receptor comparator assays.
Browse Inventory
In research literature, Semaglutide is generally treated as a 34-amino acid GLP-1 receptor agonist analog with a C18 fatty diacid modification enabling reversible albumin binding. Semaglutide binds the GLP-1 receptor (GLP-1R), a class B GPCR, with high affinity and activates Gs-coupled adenylyl cyclase to elevate intracellular cAMP. Downstream signalling proceeds via PKA-mediated phosphorylation of CREB and other substrates, with additional engagement of EPAC pathways depending on cell type. The C18 fatty diacid chain, linked at Lys26 via a short spacer, confers albumin binding (Kd ~3 µM) that extends circulating half-life to approximately one week in pharmacokinetic models — making it a standard comparator in peptide persistence and receptor-occupancy kinetic studies. Its primary sequence shares 94% homology with native GLP-1(7-36)amide.
Research interest centres on how fatty acid conjugation modulates receptor binding kinetics, internalisation rates, and cAMP desensitisation relative to shorter-acting GLP-1 analogs. The high GLP-1R selectivity (versus GcgR or GIPR) makes it a clean single-pathway reference standard in multi-receptor comparator assays. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Semaglutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Semaglutide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Semaglutide is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Semaglutide with Cagrilintide + Semaglutide, Klow, and BPC-157 + TB-500, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 5 labelled variants: 5mg, 10mg, 15mg, 20mg, and 30mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Semaglutide is generally discussed as a 34-amino acid GLP-1 receptor agonist analog with a C18 fatty diacid modification enabling reversible albumin binding. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
